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We conducted a cross-sectional study to determine
the prevalence of, and risk factors for, colonization with flu-
oroquinolone (FQ)-resistant Escherichia coli in residents in
a long-term care facility. FQ-resistant E. coli were identified
from rectal swabs for 25 (51%) of 49 participants at study
entry. On multivariable analyses, prior FQ use was the only
independent risk factor for FQ-resistant E. coli carriage and
was consistent for FQ exposures in the previous 3, 6, 9, or
12 months. Pulsed-field gel electrophoresis of FQ-resistant
E. coli identified clonal spread of 1 strain among 16 resi-
dents. Loss (6 residents) or acquisition (7 residents) of FQ-
resistant E. coli was documented and was associated with
de novo colonization with genetically distinct strains. Unlike
the case in the hospital setting, FQ-resistant E. coli carriage
in long-term care facilities is associated with clonal spread. 
T
he increasing prevalence of antimicrobial resistance
affecting hospitalized and ambulatory populations has
gained national prominence. Although this setting is less
well studied, evidence is mounting that antimicrobial
resistance is also an increasing problem in long-term care
facilities (1–5). Most research on colonization with resist-
ant bacteria in the long-term care setting has focused on
gram-positive organisms, in particular, methicillin-resist-
ant  Staphylococcus aureus and vancomycin-resistant
Enterococcus faecalis and E. faecium (6–9); substantially
fewer data address the prevalence of antimicrobial resist-
ance among gram-negative bacteria. 
Past studies in such facilities found that resistance in
gram-negative bacteria was not uncommon, whereas
resistance among isolates of Escherichia coli was unusual
(1,4,10,11). More recent investigations reported that
among hospitalized patients, residence in a long-term care
facility was a risk factor for colonization or infection with
E. coli that was resistant to higher generation
cephalosporins and to the fluoroquinolone (FQ) antimicro-
bial agents (12–15). Moreover, Weiner et al. reported that
nursing home residents were likely to be colonized with
such isolates at the time of hospital admission (15).
Finally, we recently noted significant increases over a 5-
year period in FQ-resistant E. coli in clinical isolates from
4 long-term care facilities in Pennsylvania (16). E. coli is
the most common species causing infections in the elderly
long-term care resident, primarily as a consequence of the
prevalence of urinary tract infections. FQs are the most
frequently prescribed antimicrobial class in this setting,
accounting for ≈25% of all antimicrobial prescriptions
(17,18). 
While evidence suggests that the prevalence of FQ-
resistant E. coli carriage among such residents is increas-
ing, no patient level study of risk factors for FQ-resistant
E. coli colonization has been performed in this setting (16).
We conducted this study to determine the prevalence of
fecal carriage with FQ-resistant E. coli among residents of
a single long-term care facility, to identify risk factors
associated with colonization, and to describe the ecology
of carriage of FQ-resistant E. coli over time. 
Methods
Study Site and Patient Population
This study was conducted at a single Veterans Affairs
Medical Center nursing home. This 240-bed facility, adja-
cent to a 150-bed acute-care hospital, opened in 1990 (9)
and maintains an average daily census of >95% of capaci-
ty. The demographics of the facility parallel that of the
adjacent tertiary medical center: 1% female and 50%
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ted from the adjacent medical center. Approximately 20
beds are used for patients requiring admission for skilled
nursing care.
Residents were recruited for this study from March to
July 2002 (19). All residents were considered eligible for
inclusion if informed consent was obtained. For residents
who were cognitively impaired, informed consent was
obtained from a legal guardian or medical proxy. The study
was reviewed and approved by the local institutional
review board. 
For enrolled participants, rectal swabs were obtained at
study entry. FQ-resistant E. coli were detected by a 1-step
screening procedure (19). Species identification and FQ
resistance were confirmed by automated testing (Vitek,
bioMérieux, Hazelwood, MO, USA). Because a recent
study noted excellent sensitivity and specificity (>90%) for
rectal swab specimens compared to stool culture for
detecting FQ-resistant E. coli (20), subsequent rectal swab
samples were obtained at monthly intervals to identify
changes in colonization status. 
Case-patients were defined as those for whom FQ-
resistant  E. coli was identified at the initial sampling.
Controls were defined as patients without FQ-resistant E.
coli at the initial sampling. Any study participant colonized
with both a FQ-resistant E. coli and a FQ-susceptible E.
coli was considered a case-patient. Patients with new col-
onization with FQ-resistant E. coli were defined as those
for whom the initial study sample yielded only FQ-suscep-
tible E. coli with a sample at a later time point yielding FQ-
resistant  E. coli. Patients clearing colonization with
FQ-resistant E. coli were defined as those for whom this
organism was detected at the time of initial sampling with
2 subsequent consecutive samples that yielded only FQ-
resistant E. coli. 
Data Collection
Computerized medical records were reviewed for all
patients. Patients admitted to the long-term care facility are
evaluated by a nurse practitioner and physician with a
comprehensive assessment documented at admission and
at yearly intervals. Quarterly assessments are performed
for minimal data set, functional, and mental evaluations.
Interval notes by the nurse practitioner and physician were
entered at times of clinical events. Data collection was
assisted by the fact that patients requiring hospital admis-
sion were cared for in the adjacent medical center. Medical
records for both facilities are maintained jointly. The nurs-
ing home admission note and yearly review notes con-
tained detailed problem lists. For patients who had
received care at other Veterans Affairs institutions, medical
records were available through the Veterans Affairs
Intranet. Demographic data obtained included age, sex,
race, date of admission to the facility, and dates of prior
hospitalizations at the time of study enrollment.
Records were also reviewed to identify potential risk
factors for carriage of FQ-resistant E. coli. Devices and
conditions that would interfere with normal mucosal
defense mechanisms (21) were ascertained, including
indwelling catheters, intravenous catheters, feeding tubes,
decubitus ulcers, and surgical wounds. Data on coexisting
conditions included renal insufficiency (defined as a serum
creatinine level of >2.0), liver failure, hepatitis C, cirrho-
sis, congestive heart failure, chronic obstructive lung dis-
ease, malignancy, and HIV. Disorders associated with
cognitive impairment included dementia, history of cere-
bral vascular accident, and psychiatric disorders such as
depression and schizophrenia. Low ambulatory status was
defined as requiring a wheelchair for ambulation or docu-
mentation of the patient’s being bed-bound. Pharmacy
records were reviewed for all antimicrobial use in the year
before study entry and during the period of prospective
fecal sample collection. 
Genotypic Analysis of E. coli
Up to 25 colonies of E. coli as available were sampled
from the initial patient sample, and <10 colonies were
obtained from subsequent cultures. Individual colonies
were subjected to pulsed-field gel electrophoresis (PFGE)
to determine macrorestriction polymorphisms after XbaI
restriction digestion of chromosomal DNA as described
(22,23). Clonal analysis was performed (24) per the crite-
ria of Tenover et al. (25); isolates that differed by <3 bands
were considered clonal and isolates that differed by 4 to 6
bands were considered related.
Statistical Methods
We conducted a cross-sectional study to identify risk
factors for FQ-resistant E. coli colonization. Bivariable
analysis was conducted to determine the association
between potential risk factors and such colonization; the
primary risk factor variable of interest was prior FQ use.
Although we used FQ use in the past year as the primary
measure, we also explored different cutpoints of prior FQ
use (i.e., 3, 6, and 9 months). Categorical variables were
compared by using the Fisher exact test. An odds ratio
(OR) and 95% confidence interval (CI) were calculated to
evaluate the strength of associations. Continuous variables
were compared with the Student t test or the Wilcoxon
rank-sum test, depending on the validity of the normality
assumption (26).
Stratified analyses were then performed to identify
where confounding and interaction were likely to exist for
the primary comparison of interest (i.e., FQ exposure and
FQ-resistant E. coli colonization). Stratification was per-
formed with the following variables: duration of residence
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tiles) and hospitalization in the prior year. The Mantel-
Haenszel test for summary statistics was used to evaluate
possible confounding (27); interaction was assumed when
the test for heterogeneity between the OR for different
strata was significant (p<0.05). 
Multivariable analysis was performed with multiple
logistic regression (28). Building the multivariable model
began with inclusion of key variables based on a priori
hypotheses (i.e., prior FQ use). All variables with a p value
<0.20 on bivariable analysis were also considered for
inclusion in a multivariable explanatory model (29).
Variables were also considered for inclusion in the model
if they were noted to be involved in confounding on strat-
ified analysis. Finally, we evaluated the impact of the vari-
able indicating “time at risk” (i.e., duration of residence in
the facility before study enrollment) in the multivariable
model. The interaction between risk factor variables in the
final model was also investigated. A2-tailed p value <0.05
was considered significant. All statistical calculations were
performed with standard programs in STATA v. 8.0 (Stata
Corp, College Station, TX, USA). 
Results
Of 75 randomly selected residents who were consecu-
tively approached for enrollment, 60 (80%) gave informed
consent for inclusion in the study. Five residents were dis-
charged or died before having an initial rectal sample
obtained for study; 6 other residents had stool samples that
did not yield E. coli despite multiple samplings. Thus,
samples from 49 residents yielded E. coli isolates and were
included in the study. The median age of participants was
69 years (range 38–98 years). Two (4.1%) participants
were female, 18 (36.7%) were African American, and 1
(2.0%) was Hispanic. Three residents were admitted only
for skilled nursing care. Patient functional scores exhibited
a bimodal pattern: one third of patients were considered
full care, one third as fully independent, and the remaining
patients evenly spread through a range of functional levels.
Approximately 50% of patients were incontinent. Multiple
sclerosis was documented for 5 patients. 
FQ-resistant  E. coli was detected in the stool of 25
(51%) residents (19). The median age of case-patients was
73 years (range 38–87 years) and 65.5 years (range 42–98
years) for controls (p = 0.99). One case-patient and 1 con-
trol were women (p>0.99). Ten case-patients and 8 con-
trols were African American (p = 0.77). The results of
bivariable analysis are shown in Table 1. Duration of nurs-
ing home residence, hospitalization within the 12 months
before study entry, low ambulatory status, FQ use within
the past year, and prior metronidazole use were associated
with FQ-resistant E. coli colonization. Association of FQ
exposure and colonization with FQ-resistant E. coli was
noted at all quartiles except for exposure within the 3
months before study entry: 6 (25%) of 24 controls and 18
(72%) of 25 case-patients received FQ in the 9 months
before study entry (p = 0.002); 5 (21%) of 24 controls and
14 (56%) of 25 case-patients received FQ in the 6 months
before study entry (p = 0.02); and 3 (13%) of 24 controls
and 7 (28%) 25 received FQ in the 3 months before study
entry (p = 0.29). 
On multivariable analysis, only prior FQ use remained
an independent risk factor for FQ-resistant E. coli colo-
nization (Table 2). Aborderline significant association was
seen between FQ-resistant E. coli colonization and dura-
tion of prior long-term care residence as well as prior
metronidazole use.
Genotypic analysis of 25 colonies from each study par-
ticipant was performed by PFGE. Multiple strains were
detected in initial fecal samples from 22 (44.9%) partici-
pants. For those with FQ-resistant E. coli in stool, 16
(64%) had multiple E. coli strains. In contrast, multiple
strains were less common for those not colonized with FQ-
resistant E. coli as only 6 (25%) harbored multiple strains
of E. coli (OR 5.33, 95% CI 1.34–22.23, p = 0.006). Both
FQ-resistant and FQ-susceptible E. coli were detected in
fecal samples from 15 participants. Comparison of strains
between participants documented 2 clusters of clonally
related strains of FQ-resistant E. coli detected for multiple
persons. Clone A was detected in fecal samples from 16
participants: 7 were colonized with clone A alone and 9
with strain A and >1 unique strains of FQ-resistant E. coli,
FQ-susceptible E. coli, or both (Table 3). A second resist-
ant clone, clone C, was detected in the stools from 2 par-
ticipants (Table 3). Unique stains of FQ-resistant E. coli
(i.e., other than clone Aor C) were detected in the stools of
14 (56%) persons. FQ-susceptible strains were genetically
unique in different participants. FQ exposure in patients
colonized with clone Acompared with other strains of FQ-
resistant E. coli did not differ (data not shown). Thus, per-
son-to-person clonal spread of FQ-resistant E. coli was
common and occurred in the absence of FQ exposure. 
Of the 49 participants enrolled in the study, 45 (92%)
had follow-up cultures. For the 25 participants initially
colonized with FQ-resistant E. coli, 22 (88%) had sequen-
tial follow-up cultures (median follow-up 6 months, range
1–10 months). Rectal swabs from 16 (73%) study partici-
pants continued to yield FQ-resistant E. coli at each
monthly sample, while swabs from 6 patients demonstrat-
ed clearance of this organism. The median time for clear-
ance of FQ-resistant E. coli was 5 months (range 2–10
months). For the 24 participants not initially colonized
with FQ-resistant E. coli, 23 (96%) had follow-up rectal
swab samples. New colonization with FQ-resistant E. coli
was detected in samples from 7 (30%) persons at a medi-
an of 6 months from study entry (range 1–8 months). Three
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were prescribed antimicrobial agents after study entry, but
the antimicrobial agent was not an FQ. For these 3
patients, no change in carriage of FQ-resistant E. coli
occurred. No study participant was hospitalized in the fol-
low-up period. No demographic or clinical factors were
associated with a change in colonization status. Thus,
resistance patterns were altered in a large number of study
participants (13 [29%] of 45), independent of antimicro-
bial treatment in the 1-year follow-up period. 
For the 7 study participants with newly acquired FQ-
resistant  E. coli, PFGE genotypes of all strains of FQ-
susceptible E. coli cultured from the initial study sample
were compared to 5 colonies of FQ-resistant E. coli ran-
domly chosen from the first sample yielding FQ resistance.
For each patient, PFGE genotypes differed between initial
and subsequent samples, a demonstration of de novo colo-
nization with resistant bacteria. Similarly, clearance of FQ-
resistant E. coli was associated with de novo colonization
with genetically distinct strains in 5 of 6 cases. For 1 case-
patient, a resistant strain cleared; colonization with a sus-
ceptible strain present at the initial study visit continued. 
Discussion
FQ use was the only independent risk factor for FQ-
resistant E. coli colonization. Borderline significant asso-
ciations existed between carriage of such organisms and
duration of residence in the long-term care facility before
study enrollment and prior metronidazole use. Most study
participants harboring FQ-resistant E. coli were colonized
with clonally related strains. Change in colonization status,
either acquisition or clearance of FQ-resistant E. coli, was
common in the 1-year period of follow-up and did not
appear to be related to antimicrobial therapy. 
Although never previously investigated in a long-term
care facility, the association between FQ exposure and col-
onization or infection with FQ-resistant E. coli has been
documented (30–36). Other investigators have, however,
found prior FQ exposure to represent a modest (37) or no
risk (38) for colonization with FQ-resistant E. coli.
Exposure effect was found to be relatively short-lived
among cancer patients prescribed FQ antimicrobial agents
as part of prophylaxis during chemotherapy: >75% of
patients had clearance of FQ-resistant E. coli within 3
months of ceasing FQ use (31,34). While our data corrob-
orate the relationship between FQ exposure and FQ-resist-
ant E. coli, we also found that temporally more distant FQ
exposures (>3 months) may also represent risks for colo-
nization with resistant bacteria. And, in contrast to the
findings with cancer patients, colonization with FQ-resist-
ant E. coli may persist over long periods.
We addressed the question of clearance and acquisition
of FQ-resistant E. coli in the long-term care setting. Of the
45 patients with follow-up cultures, 13 (29%) demonstrat-
ed acquisition or clearance with FQ-resistant E. coli over
the 1-year follow-up period. No patient who changed col-
onization status was treated with FQ during the 1-year
study period or in the year before study entry (data not
shown). Thus, in this closed setting, colonization with FQ-
resistant E. coli appears to be a dynamic process and may
be less affected by prior FQ therapy than it would be in the
acute-care setting. 
Molecular analysis shed further light on this process.
In all cases but one, alteration in colonization status
(whether from resistant to susceptible or susceptible to
resistant) was marked by de novo colonization with bac-
teria genetically distinct from those patients had at study
entry. For the remaining patient, a resistant strain was
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persisted. 
Most (64%) study participants colonized with FQ-
resistant E. coli harbored a single clonally related strain
(clone A); 56% were colonized with strains other than
clone A. Thus, the emergence of FQ-resistant E. coli colo-
nization in this patient population appeared to arise from
patient-to-patient spread as well as de novo resistance.
Clonal spread of FQ-resistant E. coli has not been ade-
quately addressed, although 2 studies of cancer patients
suggest that it is uncommon in other clinical settings
(34,39). 
Our study had several potential limitations. Our small
sample size may have hampered our ability to identify
smaller effect sizes for risk factors of interest. The possi-
bility of selection bias is of concern, given that only 25%
of the total population of the facility was enrolled in the
study. Since we only sampled participants monthly, the
longitudinal component of the study is limited regarding
fully characterizing the dynamics of how frequently resist-
ance profiles of nursing home residents are altered. These
factors also limit our ability to assess outcomes and risks
for subsequent infections. Changes in resistance profiles
were also associated with colonization with different E.
coli strains. Whether this represents possible antimicrobial
effects on non–E. coli affecting the ability of new strains
of E. coli to colonize the gut is unknown. Since environ-
mental cultures were not performed, we cannot exclude a
common source exposure (e.g., food or showers) to
explain a single clone’s being detected among different
patients. Finally, whether our study results can be general-
ized to other institutions is not known. 
Our study represents the first investigation of patient-
level risk factors for FQ-resistant E. coli colonization in
the long-term care setting. We found that FQ-resistant E.
coli carriage is common in such residents and that prior FQ
exposure is the only independent risk factor for such car-
riage. These finding emphasize the importance of limiting
antimicrobial drug use in general and FQ use in particular
in this setting. Unlike the hospital setting, carriage of FQ-
resistant E. coli in long-term care facilities is associated
with clonal spread. Finally, carriage of FQ-resistant E. coli
in long-term care facilities appears to represent a fluid
process, with frequent loss or acquisition of FQ-resistant
E. coli.
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